ATE437951T1 - Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2 - Google Patents

Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2

Info

Publication number
ATE437951T1
ATE437951T1 AT98922096T AT98922096T ATE437951T1 AT E437951 T1 ATE437951 T1 AT E437951T1 AT 98922096 T AT98922096 T AT 98922096T AT 98922096 T AT98922096 T AT 98922096T AT E437951 T1 ATE437951 T1 AT E437951T1
Authority
AT
Austria
Prior art keywords
hepatitis
polypeptide
shortened
intracellular production
truncated
Prior art date
Application number
AT98922096T
Other languages
English (en)
Inventor
Michael Hougton
Qui-Lim Choo
Sergio Abrignani
David Chien
Mark Selby
Edward Glazer
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE437951T1 publication Critical patent/ATE437951T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/923—Cell culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98922096T 1997-05-06 1998-05-06 Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2 ATE437951T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4567597P 1997-05-06 1997-05-06
PCT/US1998/009097 WO1998050556A2 (en) 1997-05-06 1998-05-06 Intracellular production of hepatitis c e1 and e2 truncated polypeptides

Publications (1)

Publication Number Publication Date
ATE437951T1 true ATE437951T1 (de) 2009-08-15

Family

ID=21939272

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98922096T ATE437951T1 (de) 1997-05-06 1998-05-06 Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2

Country Status (9)

Country Link
US (2) US6521423B1 (de)
EP (1) EP0980434B1 (de)
JP (3) JP4458556B2 (de)
AT (1) ATE437951T1 (de)
AU (1) AU7471698A (de)
CA (1) CA2288374A1 (de)
DE (1) DE69841015D1 (de)
ES (1) ES2328536T3 (de)
WO (1) WO1998050556A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4335099A (en) * 1998-06-18 2000-01-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Surface targeted expression of a modified hepatitis c virus envelope protein
US6432411B1 (en) * 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
JP2003512826A (ja) 1999-10-27 2003-04-08 カイロン コーポレイション Ｈｃｖ特異的ｔ細胞の活性化
US7329408B2 (en) * 1999-12-01 2008-02-12 Novartis Vaccines And Diagnostics, Inc. Eliciting HCV-specific antibodies
US7094882B2 (en) 2000-04-21 2006-08-22 Yeda Research And Development Co. Ltd. Growth factor which acts through erb b-4 rtk
CU23244A1 (es) * 2001-07-16 2007-10-17 Ct Ingenieria Genetica Biotech Formulacion vacunal potenciada por la combinacion de un adn con un antigeno
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US8029803B2 (en) * 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8025873B2 (en) * 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
RU2353399C2 (ru) 2003-01-17 2009-04-27 Этлон Медикал, Инк. Способ удаления вирусов из крови посредством лектин-аффинного гемодиализа
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
EP1574517A1 (de) * 2004-03-09 2005-09-14 Innogenetics N.V. HCV E1 beinhaltend spezifische Disulfidbrücken
EP1602664A1 (de) * 2004-03-08 2005-12-07 Innogenetics N.V. HCV E1 beinhaltend spezifische Disulfidbrücken
US20090170063A1 (en) * 2004-06-25 2009-07-02 Advanced Life Science Institute, Inc. Hcv rna having novel sequence
AU2005295317B2 (en) * 2004-10-18 2011-10-13 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
EP1948802A4 (de) * 2005-10-13 2009-01-14 Virexx Medical Corp Chimäres antigen mit hepatitis-c-virus-polypeptid und fc-fragment zum hervorrufen einer immunantwort
AU2008335457B2 (en) 2007-12-07 2015-04-16 Glaxosmithkline Biologicals S.A. Compositions for inducing immune responses
EP2331125A4 (de) 2008-09-19 2013-03-27 Globeimmune Inc Immuntherapie zur für chronische hepatitis-c-virus-infektionen
WO2015132619A1 (en) 2013-05-15 2015-09-11 The Governors Of The University Of Alberta E1e2 hcv vaccines and methods of use
US10300131B2 (en) 2015-07-07 2019-05-28 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
EP3359577A4 (de) 2015-10-08 2019-04-17 The Governors of the University of Alberta Hepatitis-c-virus-e1/e2-heterodimere und verfahren zur herstellung davon

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004669A1 (en) 1987-11-18 1989-06-01 Chiron Corporation Nanbv diagnostics and vaccines
WO1990011089A1 (en) 1989-03-17 1990-10-04 Chiron Corporation Nanbv diagnostics and vaccines
ATE211772T1 (de) 1989-05-18 2002-01-15 Chiron Corp Nanbv-diagnostika: polynukleotide, geeignet für reihenuntersuchungen auf hepatitis c-virus
US6274148B1 (en) * 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
HU227498B1 (en) 1990-11-08 2011-07-28 Novartis Vaccines & Diagnostic Process for production of hepatitis c virus asialoglycoproteins
AU3241095A (en) 1994-07-29 1996-03-04 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
EP1845108A3 (de) 1994-07-29 2007-10-24 Innogenetics N.V. Monoklonale Antikörper gegen gereinigte Hüllproteine des Hepatitis-C-Virus für diagnostische und therapeutische Zwecke
DK1510580T3 (da) * 1994-07-29 2009-02-16 Novartis Vaccines & Diagnostic Trunkeret hepatitis C E2-polypeptid og fremgangsmåder til opnåelse heraf

Also Published As

Publication number Publication date
WO1998050556A3 (en) 1999-02-11
US7429385B2 (en) 2008-09-30
JP2008195722A (ja) 2008-08-28
CA2288374A1 (en) 1998-11-12
EP0980434B1 (de) 2009-07-29
JP4458556B2 (ja) 2010-04-28
JP2009232863A (ja) 2009-10-15
EP0980434A1 (de) 2000-02-23
DE69841015D1 (de) 2009-09-10
ES2328536T3 (es) 2009-11-13
HK1023143A1 (zh) 2000-09-01
US20040001854A1 (en) 2004-01-01
AU7471698A (en) 1998-11-27
JP2002504810A (ja) 2002-02-12
US6521423B1 (en) 2003-02-18
WO1998050556A2 (en) 1998-11-12

Similar Documents

Publication Publication Date Title
ATE437951T1 (de) Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
AR018023A1 (es) Procedimiento para la fabricacion de polipeptidos con glicosilacion apropiada
ATE481480T1 (de) Methoden und zusammensetzungen zur herstellung von polypeptiden
DE69733247D1 (de) Humanisiertes grünes-fluoreszenzprotein und methoden
BR0013231A (pt) Complexos citocina-anticorpo múltiplos
DK1088084T3 (da) Erythropoietin analog-humant serumalbumin fusionsprotein
WO2000053761A3 (en) Human cytokine as ligand of the zalpha receptor and uses thereof
DE69823046D1 (de) Praktische in vitro sialylierung von rekombinanten glykpproteinen
ATE500323T1 (de) Subtilisin-variante
ATE423788T1 (de) Neues tgf-beta-ahnliches cytokin
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
NO981430L (no) Avkortet gliacellelinjeavledet neurotrof faktor
TR200000175T2 (tr) Endogenik gen aktivasyonu ile eritropoietinin hazırlanması.
BR0316324A (pt) Polipeptìdeos e conjugados de interferon-alfa
MX9704050A (es) P-amidinobencilamidas de dipeptido novedosas con radicales sulfonilo o aminosulfonilo en terminal n.
DK1025245T3 (da) Hurtig etablering af stabile pattedyrscelelinjer, der producerer höje koncentrationer af rekombinante proteiner
PT813419E (pt) Moduladores de proteinas reguladoras
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
PT1200561E (pt) Clone celular recombinante estavel, sua producao e utilizacao
DK1082423T3 (da) Cyclin E2-gener og -proteiner
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
DE69232945D1 (de) BLUTPLAETTCHEN-GPIIIa P1A1 und -P1A2-EPITOPE, IHRE HERSTELLUNG UND VERWENDUNG
DK1000154T3 (da) Identificering af humane cellelinjer til produktion af humane proteiner ved endogen genaktivering
ES2090357T3 (es) Una proteina de union a colageno asi como su preparacion.
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties